Activity Description and Educational Objectives

In this activity, an expert in cardiometabolic health discusses the role and ability of SGLT2 inhibitors to improve renal outcomes in patients with T2DM and/or CKD.

Upon completion of this activity, participants should be better able to:

• Outline the mechanism(s) of action and clinical potential of newer options in glucose-lowering therapy that have been shown to improve renal outcomes in patients with T2DM
• Evaluate the clinical efficacy and safety of newer options in glucose-lowering therapy in patients with T2DM and/or CKD
• Integrate newer glucose-lowering therapies to improve the management of patients with T2DM and/or CKD based on the latest clinical evidence

Target Audience

This activity has been designed to meet the educational needs of endocrinologists, primary care physicians, nephrologists, and other clinicians involved in the management of patients with T2DM.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: November 2, 2020 - November 1, 2021
Time to Complete: 30 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair

George L. Bakris, MD
Professor of Medicine
Director, American Heart Association
Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois

George L. Bakris, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; AstraZeneca; Bayer Corporation; Ionis Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; KBP Biosciences Co., Ltd; Merck & Co., Inc.; Novo Nordisk, Inc.; and Vascular Dynamics, Inc.

Medical Directors

Angela McIntosh, PhD
PVI, PeerView Institute for Medical Education

Angela McIntosh, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Monalisa Singh, MD, PhD
PVI, PeerView Institute for Medical Education

Monalisa Singh, MD, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6666-21-T.

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by independent educational grants from AstraZeneca LP, Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC, and Merck & Co., Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView